Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2024 14:51 ET | Source: AmeriCorps

Remarks as Prepared for CEO Michael D. Smith at the September 11 Anniversary Event

Washington, DC, Sept. 10, 2024 (GLOBE NEWSWIRE) -- CEO Smith's remarks as prepared are below. I was a recent college graduate living in Washington, DC, in the fall of 2001. The sight of the gaping...
April 15, 2024 09:00 ET | Source: Loyal Source Government Services

Loyal Source Strengthens Veteran Affair and Medical Disability Examination Program with Two Key Hires

ORLANDO, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Loyal Source Government Services, one of the nation’s leading providers of healthcare solutions for federal, state, local and commercial partners,...
October 24, 2023 20:54 ET | Source: Swords to Plowshares

Veteran Service Organizations File Lawsuit to Compel VA to Amend its Character of Discharge Regulations

Washington, D.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Today, two veterans service organizations filed a lawsuit in the U.S. Court of Appeals for the Federal Circuit to compel the U.S. Department of...
March 24, 2021 08:25 ET | Source: Arch Biopartners

Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topical Wound Treatment

TORONTO, March 24, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has entered into an exclusive agreement with the...
April 07, 2020 08:41 ET | Source: Alliant Healthcare

Veteran-Owned Healthcare Company Awarded $43 Million Contract to Aide Department of Defense (DOD) and Federal Agencies

Michigan, April 07, 2020 (GLOBE NEWSWIRE) -- Michigan-based Alliant Healthcare Products has been awarded a Laboratory ECAT contract by the Defense Logistics Agency valued at $43,750,000 over 5 years....
March 27, 2018 09:08 ET | Source: Arch Biopartners

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....